Abstract
Metastatic melanoma is well known for its aggressive clinical behavior and therapeutic resistance. The standard systemic therapy has shown limited clinical activity with no significant survival benefit. Melanoma is a molecularly heterogeneous malignancy. Several key genetic lesions governing melanoma initiation and progression have been identified, the most common being a point mutation in the BRAF proto-oncogene, which is detected in 50–60% of metastatic melanoma. The prevalence of RAF alteration in metastatic melanoma and other human cancer has prompted significant efforts in the development of BRAF targeted therapy. Several BRAF inhibitors have entered clinical trials, and have shown significant responses even in patients with late-stage melanoma. In this article, we review the rationale, clinical activity and safety of BRAF targeted therapy for metastatic melanoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
